Repathaź (evolocumab) phase 3 cognitive function study results published in NEJM
Amgen announced NEJM published results from the Repathaź (evolocumab) cognitive function trial (EBBINGHAUS), which was conducted in a subset of patients enrolled in the randomized, placebo-controlled Repatha cardiovascular outcomes study. The study demonstrated Repatha was non-inferior to placebo. August 16, 2017